NeuMedics is developing a topical formulation that can be used to treat Diabetic Macular Edema (DME), Trauma and Uveitis all are large unmet medical needs
NeuMedics has developed anti-inflammatory compounds that also have anti VEGF properties. They are being developed for topical delivery to the eye for treatment of DME. DME is the leading cause of blindness for up to 2.5 million diabetic patients in U.S.; 75,000 new cases each year in U.S. Treatment for patients suffering from this disease are limited to expensive Biologic drugs or steroids and require frequent direct injections into the eye.